Gradientech strengthens its commercial management team
The diagnostics company Gradientech today announces that AnnaLotta Schiller Vestergren has been appointed as the company’s Chief Commercial Officer and part of the management team. AnnaLotta has extensive experience with international commercial organisations, with nearly 30 years of leading positions in life science and diagnostics.
“I´m very pleased to welcome AnnaLotta to join the Gradientech team. With a background in molecular biology and bacteriology and extensive experience in international sales and business development from major life science companies as well as smaller emerging companies, I´m convinced that AnnaLotta will be a key driver for the success of the exciting phase we now are in - the threshold of a breakthrough of next-generation antibiotic susceptibility testing (AST) in routine diagnostics,” says Sara Thorslund, CEO and co-founder at Gradientech.
“Gradientech's groundbreaking QuickMIC® system is addressing crucial needs in clinical diagnostics with its speed and precision holding an immense promise for elevating antibiotic susceptibility testing to new heights, truly contributing to the advancement of next-generation diagnostics and personalised medicine. Drawing from my nearly three decades of experience in commercialisation across diverse regions, I'm looking forward to supporting Gradientech's talented team and contributing to its mission of combating the global healthcare challenges of antibiotic resistance. Joining the Gradientech team fills me with great excitement, and I can't wait to work together to achieve our commercial goals and drive the company's next phase of growth,” says AnnaLotta Schiller Vestergren, appointed CCO at Gradientech.
The QuickMIC system's ultra-rapid and precise AST results enable sepsis patients to receive specific personalised guidance of the right antibiotic and the right dose in record time. The modular design offers affordable scaling possibilities, making QuickMIC attractive to both small and large hospital laboratories. QuickMIC and its Gram-negative panel are CE marked and commercially available in Europe but not yet available for sale in the United States.
For further information, please contact:
Sara Thorslund, PhD, CEO
Tel: +46 736 29 35 80
About Gradientech
Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.
